CN Patent

CN104803992A — 阿法替尼盐的晶型

Assigned to Sunshine Lake Pharma Co Ltd · Expires 2015-07-29 · 11y expired

What this patent protects

本发明涉及阿法替尼二马来酸盐的新晶型及其制备方法，所述新晶型的X-射线粉末衍射图中在2θ为17.57,22.52,28.12,32.19,33.33,39.42度的位置的有峰，或者所述新晶型的X-射线粉末衍射图中在2θ为5.28,12.27,17.17,21.22,24.75,26.34度的位置有峰；所述新晶型具备较好的晶型稳定性和粉末流动性，可用于药物制剂。

USPTO Abstract

本发明涉及阿法替尼二马来酸盐的新晶型及其制备方法，所述新晶型的X-射线粉末衍射图中在2θ为17.57,22.52,28.12,32.19,33.33,39.42度的位置的有峰，或者所述新晶型的X-射线粉末衍射图中在2θ为5.28,12.27,17.17,21.22,24.75,26.34度的位置有峰；所述新晶型具备较好的晶型稳定性和粉末流动性，可用于药物制剂。

Drugs covered by this patent

afatinib-dimaleate (AFATINIB DIMALEATE)

Patent Metadata

Patent number: CN104803992A
Jurisdiction: CN
Classification: —
Expires: 2015-07-29
Drug substance claim: No
Drug product claim: No
Assignee: Sunshine Lake Pharma Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.